It has been a few years since Dr. Steven Nissan shook the diabetes world apart with his scathing review of the TZDs, pioglitazone and rosiglitizone. Many professionals blame him for the demise of rosiglitizone and the almost-death of pioglitazone, because of his comments on heart problems caused by the class …
Read More »Yearly Archives: 2016
SGLT-2 Patient Results
What kind of results have you seen with the use of SGLT-2 inhibitors for your patients? Follow the link to respond.
Read More »Young Women with Type 2 Diabetes Show High Rate of Congenital Anomalies
Reasons may include poor metabolic control and extreme obesity.
Read More »Question 815
A patient that you haven’t seen for several years comes to your clinic for a wellness check-up. Since her last visit, she has gained about 15 pounds (5’6”, BMI 27 kg/m2). Her stage 1 hypertension is controlled with hydrochlorothiazide. As you discuss her weight gain, you learn that she doesn’t get more than 30 minutes a week of physical activity. You decide it would be best to check her A1C. Which of the following information from her history leads you to screen her for type 2 diabetes? Follow the link to respond.
Read More »BMP7 – Creating Insulin-Producing Cells and Lowering Insulin Resistance
Agent could make transplants more available in patients with type 1 diabetes, improve insulin resistance.
Read More »What Motivates People to Use Technologies for Tracking Health?
As we all know, it is easy to start out with good intentions to be more active or manage diabetes better, but it’s much more difficult to follow through and stick with such changes so that they become sustainable. While some studies have recently shown that newer devices like the Fitbit can increase physical activity adherence, the real question is, will using the latest health information technologies be motivating enough for most people to continue doing it long-term?
Read More »A Possible Role for SGLT-2 Inhibitors in Blood Pressure Control
New studies indicate potential class effect in reducing hypertension.
Read More »Should Lower Blood Pressure Targets for Diabetic Patients be Adopted?
ACCORD trial suggests lowering blood-pressure to a target of <120 mm Hg systolic.
Read More »Liraglutide Lacks HbA1c Control in Type 1 Diabetes
New study of normal-weight patients suggests weight reduction, insulin requirements.
Read More »January 9, 2016
This week CES (Consumer Electronics Show) is in full swing in Las Vegas. There are over 180,000 attendees, and over the next four days they will look at more than 10,000 displays of products for home, auto, industrial and personal use. When we were there 3 years ago there was one …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.